4 / 4
Page 15
allied
academies
Journal of Medical Oncology and Therapeutics | Volume 4
February 25-26, 2019 | Paris, France
13
th
World Cancer Congress
Notes:
T
hedivergencebetween S6Kinase 2 (S6K2) and its homologue
S6 Kinase 1 (S6K1) has displayed that the exclusive functions
of S6K2 are very important mediators of tumor growth. Recent
studies suggest that S6K2complexeswithB-Raf andPKCε toexert
cancer cell survival. Also, indirect roles of S6K2 which involve
interaction with Akt and PDCD4 to propagate cancer cell survival
makes it an important therapeutic target. Also, centrosomal
localization of a pool of S6K2 potentiates a proliferative role.
Amplification and overexpression of
RPS6KB2
gene locus,
which encodes S6K2 protein, is observed in breast cancer and
is correlated with poor prognosis. Also, S6K2 expression is
correlated with 4EBP1 and E2F1 expression in breast cancer.
Also, breast cancer tissues display nuclear over-accumulation of
S6K2 when compared to its normal counterparts.
Currently, the mechanisms which regulate the cellular levels of
S6K2 are unknown. Also, there still remains new substrates of
S6K2 to be unraveled. As the mysteries of S6K2 is solved, new
stones are paved in the breast cancer therapy path.
Speaker Biography
Nurettin İlter Sever has completed his PhD in 2013 from The Ohio State University, USA. He
is currently an assistant professor at Pamukkale University, Denizli, Turkey. He is currently
establishing his laboratory and is a member of EACR.
e:
nsever@pau.edu.trNurettin İlter Sever
Pamukkale University, Turkey
The mysteries of S6K2 may shed light to Breast Cancer Therapy path